eHeme Malignancies Review

Dr. B. Douglas Smith, MD, Associate Professof of Oncology, Division of Hematologic Malignancies at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD, will present case scenarios which will address: developing an approach to treatmet for patietns newly diagnosed with CML, develop effective monitoring strategies for CML patients--assessing for early opportunities to adjust therapy to maxiize tolerability and response; and describe the role of allogeneic stem cell transplantation

Dr. Carol Ann Huff, Director of the Mutiple Myeloma Program and the Sidney Kimmel Comprehensive Cancer Center in Baltimore, will present case scenarios which will address evidence basis for selecting initial therapy for patients with MM, discuss strategies to reduce the incidence and severity of peripheral neuropathy in patients with MM; and discuss emerging therapeutic strategies for patients with MM

Dr. Ian W. Flinn, MD, PhD, Director of Hematologic Malignancies Research at the Sarah Cannon Research Institute in Nashville, Tennessee will present patient case scenarios which will: describe appropriate first-line treatment for patients with follicular lymphoma, explain the valeu of maintenance therapy in patients with low grade lymphoma, and discuss the role of allogeneic blood or marrow transplantation in managing patients with low grade lymphoma

Dr. Christopher Gocke, Director of Hematology Molecular Diagnostics, and Associate Professor, Department of Pathology from the Johns Hopkins University School of Medicine will present case scenarios which: describe minimal residual disease, discuss the relateive pros and cons of detecting MRD, and identifying one of the three diseases in which MRD determination play a clinical role

Our Guest Author is Louis Diehl, Professor of Medicine at the Duke University School of Medicine in Durham, North Carolina. Dr. Diehl will present patient cases which will help listeners to: Confirm the diagnosis and chronic lymphocytic leukemia (CLL) utilizing the major anatomic and biologic prognostic factors, formulate initial treatment criteria and select an initial treatment regimen for a patient with CLL, and finally select the second treatment regimen for patients who may be progression on/after initial FCR treatment.

Dr. Mikkael Sekeres, Associate Professor of medicine and Director of the Leukemia Program at the Cleveland Clinic Tassig Cancer Center, will cover presenting characteristics of the MDS patient, Describe the most appropriate patient to receive hypomethylator therapy, and identify the most appropriate therapies for higher-risk MDS.